AGRX AGILE THERAPEUTICS INC.

EQS-News: NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022

EQS-News: Agile Therapeutics, Inc.
NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022

21.10.2022 / 17:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Matt Riley - Head of Investor Relations & Corporate Communications

Company Website


News Source: News Direct

21.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Agile Therapeutics, Inc.
United States
ISIN: US00847L2097
EQS News ID: 1469705

 
End of News EQS News Service

1469705  21.10.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1469705&application_name=news&site_id=research_pool
EN
21/10/2022

Underlying

AGRXAGILE THERAPEUTICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AGILE THERAPEUTICS INC.

 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

EQS-News: This Biotech Company is Pursuing Positive Cash Flow In 2023

EQS-News: Agile Therapeutics, Inc. This Biotech Company is Pursuing Positive Cash Flow In 2023 21.12.2022 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. The Princeton, New Jersey-based company’s Twirla patch gives women the choice to not take a birth control pill every day. Instead, women can apply the patch weekly on their buttocks, lower abdomen, or upper torso, but...

December 21, 2022 1 EN
 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

EQS-News: Women’s Healthcare Company Agile Therapeutics Says It Believ...

EQS-News: Agile Therapeutics, Inc. Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow 15.11.2022 / 14:15 CET/CEST The issuer is solely responsible for the content of this announcement. Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options.The company’s product and product candidates are designed to provide women with contraceptive options that offer freedom from takin...

November 15, 2022 1 EN
 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

EQS-News: Can This Company’s Birth Control Patch Disrupt The Contracep...

EQS-News: Agile Therapeutics, Inc. Can This Company’s Birth Control Patch Disrupt The Contraceptive Market? 26.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products.While the issue of birth control and abortion can be embroiled in continuous debates and , contraceptives have b...

October 26, 2022 1 EN
 PRESS RELEASE
Free
AGRX AGILE THERAPEUT...

EQS-News: NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth...

EQS-News: Agile Therapeutics, Inc. NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022 21.10.2022 / 17:00 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsMatt Riley - Head of Investor Relations & Corporate CommunicationsCompany WebsiteNews Source: News Direct 21.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcement...

October 21, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch